An HPLC-UV validated bioanalytical method for measurement of in vitro phase 1 kinetics of α-synuclein binding bifunctional compounds

References

• Advanced Chromatography Technologies Ltd (ACE). 2020 March 2. The use of mobile phase pH as a method development tool. Chromatography Today. 24–26.
   Google Scholar
• Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. 2002. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos. 30(12):1497–1503.
   PubMed Web of Science ®Google Scholar
• Brundin P, Dave KD, Kordower JH. 2017. Therapeutic approaches to target alpha-synuclein pathology. Exper Neurol. 298(Part B):225–235.
   PubMedGoogle Scholar
• Caspar AT, Meyer MR, Maurer HH. 2018. Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach. Toxicol Lett. 285(November 2017):1–8.
   PubMed Web of Science ®Google Scholar
• Chen K, Chen X. 2010. Design and development of molecular imaging probes. Curr Top Med Chem. 10(12):1227–1236.
   PubMed Web of Science ®Google Scholar
• Chenevert R, Mohammadi-Ziarani G, Caron D, Dasser M. 1999. Chemoenzymatic enantioselective synthesis of (-)-enterolactone. Can J Chem. 77(2):223–226.
   Web of Science ®Google Scholar
• Davie CA. 2008. A review of Parkinson’s disease. Br Med Bull. 86:109–127.
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res. 10(7):1093–1095.
   PubMed Web of Science ®Google Scholar
• Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, Singleton A, Olanow CW, Merchant KM, Bezard E, et al. 2015. Targeting α-synuclein for treatment of Parkinson’s disease: mechanistic and therapeutic considerations. Lancet Neurol. 14(8):855–866.
   PubMed Web of Science ®Google Scholar
• Fields CR, Bengoa-Vergniory N, Wade-Martins R. 2019. Targeting alpha-synuclein as a therapy for Parkinson’s disease. Front Mol Neurosci. 12(December):1–14.
   PubMedGoogle Scholar
• Forno LS. 1996. Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol. 55(3):259–272.
   PubMed Web of Science ®Google Scholar
• Ghosh KK, Padmanabhan P, Yang C-T, Mishra S, Halldin C, Gulyás B. 2020. Dealing with PET radiometabolites. EJNMMI Res. 10(1):1–17.
   PubMedGoogle Scholar
• Giuliano C, Jairaj M, Zafiu CM, Laufer R. 2005. Direct determination of unbound intrinsic drug clearance in the microsomal stability assay. Drug Metab Dispos. 33(9):1319–1324.
   PubMed Web of Science ®Google Scholar
• Gundert-Remy U, Bernauer U, Blömeke B, Döring B, Fabian E, Goebel C, Hessel S, Jäckh C, Lampen A, Oesch F, et al. 2014. Extrahepatic metabolism at the body’s internal-external interfaces. Drug Metab Rev. 46(3):291–324.
   PubMed Web of Science ®Google Scholar
• Haque EM, Akther M, Azam S, Kim I, Lin Y, Lee Y, Choi D. 2022. Targeting α-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson’s disease. Br J Pharmacol. 179(1):23–45.
   PubMed Web of Science ®Google Scholar
• Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, et al. 2009. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol. 49(5):513–533.
   PubMed Web of Science ®Google Scholar
• Jakova E, Moutaoufik MT, Lee JS, Babu M, Cayabyab FS. 2022. Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson’s disease. Transl Neurodegener. 11(1):1–26.
   PubMed Web of Science ®Google Scholar
• Jasutkar HG, Oh SE, Mouradian MM. 2022. Therapeutics in the pipeline targeting a-synuclein for Parkinson’s disease. Pharmacol Rev. 74(1):207–237.
   PubMedGoogle Scholar
• John F, Muzik O, Mittal S, Juhász C. 2020. Fluorine-18-labeled PET radiotracers for imaging tryptophan uptake and metabolism: a systematic review. Mol Imaging Biol. 22(4):805–819.
   PubMed Web of Science ®Google Scholar
• Kakish J, Allen KJ, Harkness TA, Krol ES, Lee JS. 2016. Novel dimer compounds that bind alpha-synuclein can rescue cell growth in a yeast model overexpressing alpha-synuclein. A possible prevention strategy for Parkinson’s disease. ACS Chem Neurosci. 7(12):1671–1680.
   PubMed Web of Science ®Google Scholar
• Koss DJ, Erskine D, Porter A, Palmoski P, Leite M, Attems J, Outeiro TF. 2021. Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies. Acta Neuropathol Commun. 10:1–18.
   Web of Science ®Google Scholar
• Krishna DR, Klotz U. 1994. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet. 26(2):144–160.
   PubMed Web of Science ®Google Scholar
• Lin C, Krol E, Alcorn J. 2013. The comparison of rat and human intestinal and hepatic glucuronidation of enterolactone derived from flaxseed lignans. Natl Prod J. 3(3):159–171.
   Google Scholar
• Liu YQ, Mao Y, Xu E, Jia H, Zhang S, Dawson VL, Dawson TM, Li YM, Zheng Z, He W, et al. 2021. Nanozyme scavenging ROS for prevention of pathologic α-synuclein transmission in Parkinson’s disease. Nano Today. 36:101027.
   Web of Science ®Google Scholar
• Lohr JW, Willsky GR, Acara MA. 1998. Renal drug metabolism. Pharmacol Rev. 50(1):107–141.
   PubMed Web of Science ®Google Scholar
• Marotta NP, Ara J, Uemura N, Lougee MG, Meymand ES, Zhang B, Petersson EJ, Trojanowski JQ, Lee VMY. 2021. Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro. Acta Neuropathol Commun. 9(1):1–18.
   PubMed Web of Science ®Google Scholar
• Nath A, Atkins WM. 2006. A theoretical validation of the substrate depletion approach to determining kinetic parameters. Drug Metab Dispos. 34(9):1433–1435.
   PubMed Web of Science ®Google Scholar
• Nwabufo CK, Aigbogun OP. 2022. Diagnostic and therapeutic agents that target alpha ‑ synuclein in Parkinson’s disease. J Neurol. 269(11):5762–5786.
   PubMed Web of Science ®Google Scholar
• Nwabufo CK, Aigbogun OP, Allen KJH, Owens MN, Lee JS, Phenix CP, Krol ES. 2021. Employing in vitro metabolism to guide design of F-labelled PET probes of novel α-synuclein binding bifunctional compounds. Xenobiotica. 51(8):885–900.
   PubMed Web of Science ®Google Scholar
• Nwabufo CK, El-Aneed A, Krol ES. 2019. Tandem mass spectrometric analysis of novel caffeine scaffold-based bifunctional compounds for Parkinson’s disease. Rapid Commun Mass Spectrom. 33(23):1792–1803.
   PubMed Web of Science ®Google Scholar
• Obach RS. 2001. The prediction of human clearance from hepatic microsomal metabolism data. Curr Opin Drug Discov Devel. 4(1):36–44.
   PubMedGoogle Scholar
• Obach RS, Reed-Hagen AE. 2002. Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos. 30(7):831–837.
   PubMed Web of Science ®Google Scholar
• Otaru S, Niemikoski H, Sarparanta M, Airaksinen AJ. 2020. Metabolism of a bioorthogonal PET tracer candidate [19F/18F]SiFA-tetrazine in mouse liver microsomes: biotransformation pathways and defluorination investigated by UHPLC-HRMS. Mol Pharm. 17(8):3106–3115.
   PubMedGoogle Scholar
• Poewe W. 2009. Treatments for Parkinson disease-past achievements and current clinical needs. Neurology. 72(Issue 7, Supplement 2):S65–S73.
   PubMedGoogle Scholar
• Rowland M, Benet LZ, Graham GG. 1973. Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm. 1(2):123–136.
   PubMedGoogle Scholar
• Samii A, Nutt JG, Ransom BR. 2004. Parkinson’s disease. Lancet. 363(9423):1783–1793.
   PubMed Web of Science ®Google Scholar
• Schneider D, Oskamp A, Holschbach M, Neumaier B, Bauer A, Bier D. 2019. Relevance of in vitro metabolism models to PET radiotracer development: prediction of in vivo clearance in rats from microsomal stability data. Pharmaceuticals. 12(2):12–57.
   Web of Science ®Google Scholar
• Schwaninger AE, Meyer MR, Barnes AJ, Gorelick DA, Goodwin RS, Huestis MA, Maurer HH. 2011. Investigation on the enantioselectivity of the sulfation of the dihydroxymethamphetamine and 4-hydroxy-3-methoxymethamphetamine using the substrate-depletion approach. Drug Metab Dispos. 39(11):1998–2002.
   PubMed Web of Science ®Google Scholar
• Shihabuddin LS, Brundin P, Greenamyre JT, Stephenson D, Sardi SP. 2018. New frontiers in Parkinson’s disease: from genetics to the clinic. J Neurosci. 38(44):9375–9382.
   PubMed Web of Science ®Google Scholar
• Smith G, Carroll L, Aboagye EO. 2012. New frontiers in the design and synthesis of imaging probes for PET Oncology: current challenges and future directions. Mol Imaging Biol. 14(6):653–666.
   PubMed Web of Science ®Google Scholar
• Sodhi JK, Benet LZ. 2021. Successful and unsuccessful prediction of human hepatic clearance for lead optimization. J Med Chem. 64(7):3546–3559.
   PubMed Web of Science ®Google Scholar
• Turner D B, Rostami-Hodjegan A, Tucker GT, Yeo KR. 2006. Prediction of non-specific hepatic microsomal binding from readily available physicochemical properties. [accessed 2022 Sept 8]. https://www.Certara.Com/Wp-Content/Uploads/Resources/Posters/DavidISSX2006.Pdf.
   Google Scholar
• Uno S, Fujii A, Komura H, Kawase A, Iwaki M. 2008. Prediction of metabolic clearance of diclofenac in adjuvant-induced arthritis rats using a substrate depletion assay. Xenobiotica. 38(5):482–495.
   PubMed Web of Science ®Google Scholar
• Uversky VN. 2008. Alpha-synuclein misfolding and neurodegenerative diseases. Curr Protein Pept Sci. 9(5):507–540.
   PubMed Web of Science ®Google Scholar
• Vasili E, Dominguez-Meijide A, Flores-León M, Al-Azzani M, Kanellidi A, Melki R, Stefanis L, Outeiro TF. 2022. Endogenous levels of alpha-synuclein modulate seeding and aggregation in cultured cells. Mol Neurobiol. 59(2):1273–1284.
   PubMed Web of Science ®Google Scholar
• Wilkinson GR, Shand DG. 1975. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 18(4):377–390.
   PubMed Web of Science ®Google Scholar
• Williams-Gray CH, Worth PF. 2016. Parkinson’s disease. Medicine. 44(9):542–546.
   Google Scholar
• Winiwarter S, Chang G, Desai P, Menzel K, Faller B, Arimoto R, Keefer C, Broccatell F. 2019. Prediction of fraction unbound in microsomal and hepatocyte incubations: a comparison of methods across industry datasets. Mol Pharm. 16(9):4077–4085.
   PubMed Web of Science ®Google Scholar
• Yahi N, Di Scala C, Chahinian H, Fantini J. 2022. Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson’s disease. Glycoconj J. 39(1):1–11.
   PubMed Web of Science ®Google Scholar
• Yedlapudi D, Joshi GS, Luo D, Todi SV, Dutta AK. 2016. Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model. Sci Rep. 6(1):12.
   PubMedGoogle Scholar
• Youdim K, Dodia R. 2010. Comparison between recombinant P450s and human liver microsomes in the determination of cytochrome P450 Michaelis–Menten constants. Xenobiotica. 40(4):235–244.
   PubMed Web of Science ®Google Scholar
• Zhang G, Xia Y, Wan F, Ma K, Guo X, Kou L, Yin S, Han C, Liu L, Huang J, et al. 2018. New perspectives on roles of alpha-synuclein in Parkinson’s disease. Front Aging Neurosci. 10:1–20.
   PubMedGoogle Scholar